Experience with the Oncomine Precision Assay on Genexus System

Presented at: OncomineWorld 2022: A Virtual NGS Education Meeting

Speaker

Leomar Ballester, MD, PhD

Assistant Professor, Molecular Genetic Pathology and Neuropathology, Co-Director, Molecular Diagnostics Laboratory, University of Texas Health Science Center at Houston
BIOGRAPHY

Abstract

In examining the potential adoption of the Oncomine Precision Assay, University of Texas Health had several criteria to consider, including the need for highly accurate detection of small samples quickly, despite having a small lab staff (three people). This session will examine the variety of mutations which the OPA Assay detects, and how the adoption of the Ion Torrent Genexus System allowed UT Health to minimize bench time and reduce turnaround time to as little as 2 days. Mutations reviewed will include NTRK, MET, ERBB2(HER2), ERBB3 EGFR, ESR1, RET, EML4-ALK, FGFR1, KRAS, BRAF, and more.

Learning Objectives:

1. Be able to describe the benefits of the Oncomine Precision Assay(OPA) for oncology on the Ion Torrent Genexus System

2. Be able to evaluate the various mutations detected by OPA assay in the testing of human research samples